Polyrizon Ltd. (Nasdaq: PLRZ), a development stage biotech company, has announced positive preclinical data for its nasal protection platform. The company conducted ex vivo studies in collaboration with Prof. Fabio Sonvico's laboratory, utilizing excised rabbit nasal mucosa to assess the surface coverage and mucoadhesive performance of its proprietary intranasal hydrogel formulation. The studies demonstrated that Polyrizon's formulation rapidly spreads and uniformly covers the nasal mucosa, forming a consistent surface layer. The formulation also exhibited strong and lasting mucoadhesion, even under simulated physiological nasal fluid flow conditions. These findings suggest the potential for effective localized protection or therapeutic delivery, enhancing the formulation's potential efficacy in real-world scenarios.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.